MedTrace Logo

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

NCT04297605 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-02-09

No results posted yet for this study

Summary

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg

OTHER

Pemetrexed (Chemotherapy)

500 mg/m2 day 1 of 21 day cycle (for non-squamous only)

OTHER

Nab-paclitaxel (Chemotherapy)

100 mg/m2 days 1,8 of 21 day cycle x 4 cycles

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Megan Baumgart · University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2027-11-30
Completion
2028-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04297605 on ClinicalTrials.gov